Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 11;14(1):5884.
doi: 10.1038/s41598-024-53172-3.

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

Shuqing Li #  1 , Zhihui Yi #  2 , Mingqing Li  2 , Zhiling Zhu  2
Affiliations

An analysis of adjuvant chemoradiotherapy versus chemotherapy on the survival rates for patients with stage IB-III uterine serous carcinoma

Shuqing Li et al. Sci Rep. .

Abstract

The aim of the present study was to investigate whether a combination of chemotherapy plus radiotherapy was able to increase the overall survival rates compared with chemotherapy alone in stage IB-III uterine serous carcinoma. A total of 1096 patients (593 who had not received radiotherapy, and 503 who had) with primary stage IB-III uterine serous carcinoma who underwent surgery and received chemotherapy were included in the present study. The Kaplan-Meier method and Log-Rank tests showed that radiotherapy did not increase 5-year overall survival rates compared with the no-radiotherapy groups (52.3 cf. 50.8%, respectively; P = 0.641). Cox regression analysis subsequently corroborated that radiotherapy did not affect the 5-year overall survival rate (P = 0.635). Patients who were aged ≥ 60 years had a higher mortality rate [hazard ratio (HR), 1.712; 95% confidence interval (95% CI), 1.385-2.117; P < 0.05]. The 5-year overall survival rates were found to be lower in the groups where the regional lymph nodes had not been removed (HR 0.645; 95% CI 0.508-0.821; P < 0.05). Chemotherapy plus radiotherapy was found to not be associated with improved 5-year overall survival rates. However, chemotherapy may be a better treatment option for patients with primary stage IB-III uterine serous carcinoma who have undergone surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Yadav G, Roque DM, Bellone S, et al. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecol. Oncol. 2022;166(2):351–357. doi: 10.1016/j.ygyno.2022.05.021. - DOI - PubMed
    1. Albright BB, Monuszko KA, Kaplan SJ, et al. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2021;225(3):237. doi: 10.1016/j.ajog.2021.04.254. - DOI - PMC - PubMed
    1. Kurnit KC, Nobre SP, Fellman BM, et al. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol. Oncol. 2022;167(3):452–457. doi: 10.1016/j.ygyno.2022.09.025. - DOI - PMC - PubMed
    1. Monk BJ, Smith G, Lima J, et al. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. Gynecol. Oncol. 2022;164(2):325–332. doi: 10.1016/j.ygyno.2021.12.008. - DOI - PubMed
    1. Gemer O, Segev Y, Helpman L, et al. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study. Am. J. Obstet. Gynecol. 2018;219(2):181. doi: 10.1016/j.ajog.2018.05.013. - DOI - PubMed